President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET

Management available for one-on-one meetings with investors during the conference

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, in New York City.

During the presentation, Mr. Luther will provide an overview of Ernexa’s focused oncology strategy and recent progress with ERNA-101, the Company’s lead oncology cell therapy candidate. The presentation will highlight Ernexa’s differentiated, off-the-shelf-induced mesenchymal stem cell, or iMSC, platform, the growing body of preclinical evidence supporting ERNA-101 and the Company’s planned transition toward clinical development.

Presentation Details for Conference Attendees:

Conference: H.C. Wainwright 28th Annual Global Investment Conference
Presenter: Sanjeev Luther, President & CEO
Date: Wednesday, September 16, 2026
Time: 12:00 p.m. ET
Location: Kennedy I, 4th Floor

In addition to the presentation, Ernexa management will be available for one-on-one meetings with qualified investors during the conference. Investors interested in meeting with Ernexa management are encouraged to contact their H.C. Wainwright representative to request a meeting.

For more information about the conference, please visit the conference website.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.
The partnership is based on a shared conviction: that innovative medicines and certain mature medicines have different needs and should benefit from operating models tailored to their specific manufacturing, regulatory and commercial requirements. Cheplapharm’s specialized expertise will ensure these medicines continue to meet patients’ needs throughout the next stage of their lifecycle.

“Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them. Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio. This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs,” said Thomas Grenier, Executive Vice President, General Medicines, Sanofi.

“This partnership marks a major milestone for Cheplapharm. Through this project, we are incorporating products that complement our extensive portfolio, as well as the expertise and manufacturing capabilities required to produce a flagship product, Lovenox®/Clexane®. This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients.” “We are proud to pursue this ambition alongside Sanofi,” said Edeltraud Lafer and Sebastian Braun, both Co-CEOs of Cheplapharm. 

As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees). The teams would continue their activities with existing employment arrangements and collective agreements maintained. Sanofi and Cheplapharm will work closely together to ensure a smooth transition and continuity of supply in compliance with the highest manufacturing quality standards.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027, followed by the transfer of the sites, subject to employee information and consultation procedures with employee representatives, regulatory approvals and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.

For Cheplapharm, this partnership represents an important step ensuring the continuity of its strategic growth. For Sanofi, it will enable the company to continue focusing its efforts on innovation, while supporting certain established medicines through the next stage of their lifecycle.

Financial considerations for Sanofi 
The proposed transaction is not expected to have any impact on Sanofi’s financial guidance for 2026. The medicines being divested from Sanofi include Lovenox/Clexane (enoxaparin)1. Additional financial details are expected to be provided at a later stage.

 [1] Excluding in the US.

 

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Cheplapharm 
Cheplapharm  is a European family-owned pharmaceutical company based in Germany, specializing in well-established originator medicines. Driven by a long-term vision of sustainable growth, the Group has invested more than €6.2 billion since its inception, acquired nearly 100 products since 2015, and holds 3,440 marketing authorizations across 160 countries. Cheplapharm is the market leader in France and a leading European player in this market segment.

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Laura Romby | +33 6 74 16 74 29 |  laura.romby@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com 
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com 

Investor Relations
Thomas Kudsk Larsen | + 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Press contact Cheplapharm
Sandra Ammara : +33 6 79 92 71 34 – communication@cheplapharm.fr 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. 
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” “outlook,” “guidance,” or the negative of these, and similar expressions are intended to identify forward-looking statements. 
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete capital markets or other transactions, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with developing standalone businesses and with intellectual property, as well as any related pending or future litigation and the ultimate outcome of such litigation; and other risks associated with  trends in exchange and interest rates, volatile economic, political and financial and market conditions, cost containment initiatives, and the impact that global crises may have. More specifically regarding the transaction described above, these risks and uncertainties include among other things the possibility that the transaction will not be completed, or if completed, will not be completed in the expected timeframe, an unexpected failure to satisfy the required closing conditions, or unexpected delays in meeting these requirements, the ability to obtain regulatory clearances, the possibility that the expected strategic benefits, synergies or opportunities from the transaction may not be realized, or may take longer to realize than expected. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. 
All trademarks mentioned in this press release are the property of the Sanofi group.

 

Attachment

Founder and CEO outlines NextNRG’s vision, technology platform and path forward

MIAMI, FL, Sept. 14, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (Nasdaq: NXXT) (“NextNRG” or the “Company”), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced that Founder and Chief Executive Officer, Michael D. Farkas, has issued the following letter to the Company’s shareholders outlining his perspective on NextNRG’s business, technology platform and opportunities ahead:

Letter to Our Shareholders

I have spent the better part of my career building companies in industries that were changing before the market fully understood where they were going. I founded NextNRG with the same conviction: that the way businesses produce, store and use energy is changing, and that the companies willing to build for that future will have an opportunity to create lasting value.

I still believe that as strongly as I did when we started. I want to take this opportunity to speak directly to you about where we are headed.

The market will always put a price on a company. Our job is to build the company that ultimately determines what that price is worth. That is where my focus is.

NextNRG is building an integrated energy platform around a simple idea: businesses need more agency over how they generate, store and use energy. Our opportunity is to bring together the technology, infrastructure and operating capabilities to help them do that.

We have spent years building the foundation for that opportunity. We have developed technology, established an operating business, secured agreements and developed a pipeline of projects that we believe can become sources of future revenue, including, in the healthcare sector alone, multiple facility projects at different stages of development.

Projects like these take real time to move from an agreement to operational, and that timeline is not always visible from the outside. But the work behind the scenes is real, and it is where our team remains focused.

And we are beginning to see opportunities to extend the value of capabilities we have already built beyond their original purpose.

That is how I think about NextNRG’s future. We are building on what we have already created while continuing to look for opportunities to expand the value of our technology and infrastructure. The goal is not to chase every opportunity. It is to build businesses around capabilities we believe have real value, and to execute against opportunities we believe make sense for NextNRG.

There is more in the pipeline, and we will announce each project when it is signed, not before. Our focus is on turning the opportunities in front of us into operating projects and new sources of revenue.

I founded NextNRG. I am deeply invested in its future, and I have not sold a share of my position.

Our job now is to execute and be straightforward with our shareholders about how it is going.

I believe in what we are building, and I believe the opportunity ahead of NextNRG is significant.

Michael D. Farkas

Founder and Chief Executive Officer

NextNRG, Inc.

About NextNRG, Inc.

NextNRG, Inc. (NextNRG) is Powering What’s Next by deploying its AI-driven Smart Controller, a proprietary AI technology that continuously optimizes how energy is generated, stored, and consumed. The Company deploys the controller within microgrids at commercial, healthcare, municipal, industrial and federal sites, and at a utility scale through the Next Utility Operating System®.

NextNRG also sells EV chargers, is advancing wireless in-motion charging, and operates one of the nation’s largest on-demand mobile fueling fleets through EzFill.

To learn more, visit www.nextnrg.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations ContactNextNRG, Inc.
Sharon Cohen
SCohen@nextnrg.com

MONTERREY, Mexico, Sept. 14, 2026 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) today announced that, as part of its ongoing efforts and consistent with its capital allocation framework and commitment to enhance capital returns to shareholders, it has entered into a new derivative instrument known as an accelerated share repurchase (“ASR”) agreement with a financial institution in the United States of America to repurchase Company’s shares through the acquisition of American Depositary Shares (“ADS”). Under the terms of the ASR agreement, FEMSA has agreed to repurchase from such financial institution an aggregate amount of up to USD $280 million of its ADS1, subject to market conditions and delivered at maturity.

The final number of ADSs repurchased and delivered under the ASR agreement will be based on the daily volume-weighted average ADS price during the agreement term, less a discount, and subject to the agreement’s terms and conditions. Final settlement is expected to occur before year-end 2026.

About FEMSA
FEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in two core sectors, retail and beverages. In retail, FEMSA is present through four divisions: i) OXXO Mexico, operating the largest small-format store chain in Mexico; ii) Americas & Mobility, which includes its OXXO convenience store operations across Latin America and the United States, as well as its gas station business in Mexico and the United States; iii) Europe, operating convenience and foodvenience formats in five European countries; and iv) FEMSA Health, which includes drugstores and related activities in four Latin American countries. In Mexico, OXXO’s operations are enhanced by, and comprise a customer-focused ecosystem with Spin, a digital platform that leverages the OXXO store network to provide Mexican consumers with access to digital financial services, including Spin by OXXO and Spin Premia, among other initiatives. In the beverage sector, FEMSA participates through Coca-Cola FEMSA, the largest franchise bottler of Coca-Cola products in the world by volume. Across its business units, FEMSA has more than 369,000 employees in 18 countries. FEMSA is a member of the Dow Jones Best-in-Class World Index & Dow Jones Best-in-Class MILA Pacific Alliance Index, both from S&P Global; FTSE4Good Emerging Index; MSCI EM Latin America ESG Leaders Index; S&P/BMV Total México ESG, among other indexes.

__________________________________________________
1
ADS underlying units consist of 10 of FEMSA’s BD Units, each representing one Series B Share, two Series D-B Shares and two Series D-L Shares, without par value.

CONTACT: Investor Contact
(52) 818-328-6000
investor@femsa.com
femsa.gcs-web.com

Media Contact
(52) 555-249-6843
comunicacion@femsa.com
femsa.com

Artea Bankas AB, company code 112025254, address of the head office Tilžės str. 149, Šiauliai, Lithuania.

Artea bankas AB has received the notification of the persons, closely associated with the manager, in securities issued by the bank (attached). 

Additional information: 
Arnas Šukys 
Head of Investor Relations
arnas.sukys@artea.lt, +370 610 44447

Attachment

Highlights 3nm Production, 2nm Design, 3DIC Capabilities and Multi-Die Advanced Packaging

SAN JOSE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Alchip Technologies, the high-performance ASIC leader, will showcase its leading-edge process technology and advanced packaging achievements in Booth 1705 at AI Infra Summit 2026.

The event runs from September 15 through September 17 at the Santa Clara Convention Center in Santa Clara, California.

At the exhibit, Alchip will discuss its 3nm designs in production and 2nm designs currently in development. The company will also showcase its complete 2nm design platform, 3nm I/O chiplet support, and functional optical interconnect capabilities. Today, 90% of the company’s designs use process technologies below 7nm.

Alchip will also focus on its advanced packaging capabilities, highlighting its 3DIC ecosystem readiness and experience working with multiple TSMC CoWoS® technologies. These capabilities include TSMC 2nm CoWoS® designs, TSMC CoWoS®-S and TSMC CoWoS®-R designs in production, TSMC CoWoS®-L and TSMC SoIC®-X designs in development. The company will highlight its proven 3DIC capabilities, co-packaged optics technology and high-performance die-to-die IP.

Alchip has completed more than 650 successful tape-outs since its founding in 2003 and currently completes 10 to 20 new tape-outs annually. Its track record covers more than 60 FinFET designs and more than 20 CoWoS designs, with a focus on AI and high-performance computing, networking and automotive applications.

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global High-Performance Computing and AI infrastructure ASIC provider of IC and packaging design, and production services for companies developing complex and high-volume ASICs and SoCs.  Alchip provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced process technology. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D CoWoS packaging, chiplet design, and manufacturing management. Customers include global leaders in artificial intelligence, high-performance computing, supercomputing, mobile communications, entertainment device, networking equipment, and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661).

Note: CoWoS®, CoWoS®-S and CoWoS®-R, CoWoS®-L, SoIC®, and related advanced packaging terminology are trademarks or registered trademarks of Taiwan Semiconductor Manufacturing Company Limited (TSMC). They are used here solely to describe TSMC technologies incorporated within Alchip’s design and development activities.

For more information, please visit our website: http://www.alchip.com

CONTACT: Charles Byers
Alchip Technologies
+ (408)-310-9244
chuck_byers@alchip.com

ANDOVER, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today released its 2026 Environmental, Social, Governance (“ESG”) Report, outlining how MKS continues to integrate sustainability into its strategy, operations, and decision-making to support long-term value creation.

“At MKS, operational excellence, risk management, and responsible growth, together with an unwavering commitment to innovation, integrity, and trust, are foundational to our sustainability efforts,” said John T.C. Lee, President and CEO. “This report details MKS’ continued progress in improving efficiency, reducing resource use, and supporting safer, more reliable operations, while making targeted investments that strengthen our global footprint and bring our expertise and resources closer to our customers.”

The 2026 ESG Report also highlights several of our key ESG achievements since the beginning of 2025, including:

  • Science Based Targets initiative (SBTi) approval of MKS’ near-term Scope 1, 2, and 3 greenhouse gas (GHG) emissions reduction targets.
  • Generation of approximately 1,500 MWh of electricity from a new rooftop solar installation at MKS’ Guangzhou, China equipment factory, avoiding nearly 900 tCO2e emissions annually.
  • Achievement of a record 91% participation rate in MKS’ fifth annual Global Employee Engagement Survey.
  • Continued external ESG recognition, including a low ESG risk rating from Sustainalytics and recognition as one of the Best Companies to Work For by U.S. News & World Report, one of America’s Best Midsized Companies by Time and Statista, Inc. and one of America’s Most Responsible Companies by Newsweek and Statista, Inc.

The report is available to view here and includes relevant disclosures related to The Sustainability Accounting Standards Board (SASB) and The Task Force on Climate-related Financial Disclosures (TCFD) standards.

About MKS Inc.
MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding MKS’ environmental goals. Any statements that are not statements of historical fact should be considered to be forward-looking statements. Actual events or results may differ materially from those in the forward-looking statements set forth herein as a result of various important factors, including the factors described in MKS’ Annual Report on Form 10-K for the year ended December 31, 2025, and any subsequent Quarterly Reports on Form 10-Q, as filed with the U.S. Securities and Exchange Commission. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Contacts:

Bill Casey
Vice President, Marketing
Telephone: +1 (630) 995-6384
Email: press@mksinst.com

Kerry Kelly, Partner
Kekst CNC
Email: kerry.kelly@kekstcnc.com

Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms

SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies — myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms (t-MN). The studies, published in Modern Pathology, the International Journal of Cancer, and npj Precision Oncology, reinforce a growing body of evidence that OGM can detect prognostically important structural genomic alterations that elude standard karyotyping, FISH, and targeted sequencing panels.

MD Anderson Cancer Center: Chromoanagenesis by OGM defines an ultra-high-risk MDS subset.

Researchers at The University of Texas MD Anderson Cancer Center, led by Guilin Tang, PhD, used OGM to study 332 samples from subjects with MDS, identifying chromoanagenesis (CAG), a catastrophic single-event genomic restructuring process, in 15.9% of cases overall and 17.6% of newly diagnosed subjects. The study, published in Modern Pathology (Wei et al., 2026), found that:

  • CAG-positive by OGM subjects had a median overall survival of just 9.9 months, significantly shorter than non-CAG subjects where median survival was not reached.
  • CAG by OGM showed the potential to confer prognostic information beyond existing risk-stratification systems, potentially enabling the identification of patients for early allogeneic transplantation or TP53-targeted clinical trials.


University of Oulu
: Cryptic structural variants uncovered in “normal karyotype” AML.

A separate study from the University of Oulu and collaborators, led by Tuomo Mantere, PhD, used OGM to analyze 48 samples of cytogenetically normal AML (CN-AML) — a subgroup that appears unremarkable on standard karyotyping but is clinically heterogeneous. Published in the International Journal of Cancer (Turtinen et al., 2026), the study found that:

  • OGM detected clinically relevant structural variants or copy-neutral loss-of-heterozygosity in 46% of cases classified as “normal” by conventional karyotyping.
  • Recurrent alterations included KMT2A partial tandem duplications (10% of cases), RUNX1 disruptions, NF1 deletions, and a novel putative FOXP1:EYA2 fusion not previously reported in the literature.
  • Subjects with OGM-detected abnormalities had significantly worse overall survival than those without (p = 0.005).

Josep Carreras Leukaemia Research Institute: OGM refines risk in therapy-related neoplasms and younger MDS.

A multicenter Spanish study led by Mar Mallo, PhD, and Francesc Solé, PhD, at the Josep Carreras Leukaemia Research Institute in collaboration with a Spanish hospital network applied OGM to two clinically distinct: 48 subjects with therapy-related myeloid neoplasms (t-MN) and 65 subjects with younger-onset MDS (yMDS, age ≤60). Published in npj Precision Oncology (Mestre et al., 2026), the study found that:

  • OGM was interpretable in 100% of samples, including all 8 cases where conventional banding analysis (CBA) failed due to lack of dividing cells, and identified 134 additional genomic alterations.
  • OGM refined cytogenetic classification in 52.0% of karyotypically abnormal cases and detected clinically relevant structural alterations in 9.8% of cases with a normal karyotype, including reclassification of subjects into the therapeutically relevant MDS with isolated 5q- category.
  • OGM-defined genomic complexity was independently associated with overall survival; chromoanagenesis emerged as the strongest independent predictor of inferior survival in multivariable analysis (HR 9.26), exceeding even TP53 mutation status.
  • Integrating OGM findings into IPSS-R and IPSS-M scoring shifted 16.7% of t-MN and up to 12.8% of yMDS subjects into higher-risk prognostic categories, which could have implications for treatment planning, including identification of biallelic TP53 inactivation.

Key highlights across all three studies:

  • Three independent academic centers, spanning the U.S., Finland, and Spain, each show the potential for OGM to identify clinically actionable genomic complexity that conventional cytogenetic workups miss.
  • All three studies link OGM findings directly to overall and/or disease-specific survival.
  • Findings support a potential role for OGM in refining prognostication beyond IPSS-R/IPSS-M and ELN2022 classification systems, including in patients who otherwise appear lower-risk by standard testing, and in cases where conventional karyotyping fails outright due to lack of dividing cells.
  • Across all three cohorts, chromoanagenesis and TP53 disruption consistently emerge as markers of a biologically distinct, ultra-high-risk disease subset best captured by genome-wide structural variant detection.

“These three independent studies, spanning MDS, AML, and therapy-related myeloid neoplasms, all point to the same conclusion: a meaningful fraction of high-risk genomic complexity in myeloid malignancies is simply invisible to conventional karyotyping,” said Al Luderer, PhD, chairman and interim chief executive officer of Bionano. “As OGM adoption continues to expand, we expect to see more of this kind of evidence connecting structural variant detection directly to potential patient outcomes and treatment decisions.”

Turtinen et al.: https://doi.org/10.1002/ijc.70548
Wei et al.: https://doi.org/10.1016/j.modpat.2026.101031
Mestre et al.: https://doi.org/10.1038/s41698-026-01671-z

About Bionano Genomics
Bionano is a provider of genome analysis solutions that enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services, and software. Bionano offers OGM solutions for applications across basic, translational, and clinical research, as well as an industry-leading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding market adoption of our products; our commercial prospects and future financial and operating results; and the utility of OGM for the applications referenced in this press release. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: our ability to improve our margins, extend our cash runway and reach a potential pathway to profitability; our ability to continue as a going concern as disclosed in our filings with the SEC, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to execute on our strategy and achieve our objectives; the impact and utility of our cost savings initiative and our recent financing; our ability to continue to drive OGM (as defined above) adoption by potential customers for routine use in genomic analysis; the impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; the impact of our Stratys™ system and VIA™ software to increase throughput and simplify analysis of OGM data; our ability to drive adoption of OGM and our technology solutions; our ability to further deploy new products and applications for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; our ability to consummate any strategic alternatives including the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; our ability to manage the growth of our business and integrate acquired businesses; the fact that we are limited to “research use only” with respect to many of the materials and components used in our consumable products including our assays; our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; our ability to compete effectively in a competitive industry; the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies; the performance of our third-party contract sales organizations, suppliers and manufacturers; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; the impact of adverse geopolitical and macroeconomic developments, such as recent and future bank failures, ongoing international conflicts, and related sanctions, regional or global pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions; on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business; our ability to realize the anticipated benefits and synergies of our prior and any future acquisitions or other strategic transactions; our ability to attract collaborators and strategic partnerships; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025, any subsequently filed Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACT

Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817

LAVAL, Québec, Sept. 14, 2026 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces today that its Board of Directors has approved an increase to the Corporation’s monthly dividend, raising it to 4.916 cents (0.04916 $) per common share. On an annual basis, this represents an increase of three cents ($0.03) or 5.36%, raising the dividend to 59 cents ($0.59) per common share. This increase will apply to the dividends payable monthly starting on October 9, 2026, to shareholders of record of the Corporation at the close of business on September 30, 2026. This is an eligible dividend within the meaning of the Income Tax Act (Canada).

A Word from the Executive Chairman

“As a result of our financial performance in 2025 and for the first six months of 2026, I am pleased to announce an increase in our dividend. This dividend increase reflects our confidence in continuing to deliver strong profitability in the coming years, while maintaining ample balance sheet flexibility by paying down debt and having the ability to invest in growth opportunities as they arise. So far in 2026 we have invested or have committed to invest approximately $40M by year end across acquisitions, including Vipal S.p.A. in Italy and Baxter in Texas, as well as the expansion of our manufacturing plant in Greenville, South Carolina.”, said Marcel Bourassa, Executive Chairman.

About Savaria Corporation

Savaria Corporation (corp.savaria.com) is one of the global leaders in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as elevators for home and commercial use, stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and dumbwaiters. In addition, Savaria manufactures and markets a comprehensive selection of pressure management products, medical beds, as well as an extensive line of medical equipment and solutions for the safe movement of patients, such as transfer, lifting and repositioning aids. The Corporation operates a sales network of dealers worldwide and direct sales offices in North America, Europe (UK, Netherlands, Switzerland, Italy, Germany, Poland and Czech Republic) and Australia. Savaria employs approximately 2,550 people globally and its plants are located across Canada, the United States, Mexico, Europe and China.

For further information:

Sébastien Bourassa
President and CEO
1. 800.661.5112 
sb@savaria.com
Stephen Reitknecht, CPA, CA
Chief Financial Officer
1.800.661.5112, ext. 3370
sreitknecht@savaria.com
 

Facebook : https://www.facebook.com/savariabettermobility
Instagram :https://www.instagram.com/savariacorp/
LinkedIn: https://ca.linkedin.com/company/savaria

WEST PALM BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — Chatham Lodging Trust (NYSE: CLDT), a lodging real estate investment trust (REIT) that invests in upscale, extended-stay hotels and premium-branded, select-service hotels, today announced the appointment of Liam Brown to the company’s board of trustees, effective immediately. Brown will serve as an independent director.

Brown formerly was group president, United States and Canada of Marriott International, Inc., (“Marriott”) from January 2021 until his retirement in June 2026. In that role, he was responsible for the financial management and leadership of Marriott’s lodging operations in North and South America, comprising more than 6,000 hotels and a workforce of approximately 160,000 associates. Prior to this role, Brown served as the president and managing director of Europe of Marriott from 2018 to 2019, followed by group president of Europe, Middle East & Africa of Marriott in 2020. He joined Marriott in 1989 and served as president for franchising, owner services and managed by Marriott select brands, North America, from 2012 to 2018. Brown held other key positions with Marriott, including chief operations officer for the Americas for select service & extended stay lodging and owner & franchise services, as well as senior vice president and executive vice president of development for Marriott’s select service & extended stay lodging products.

Jeffrey H. Fisher, Chatham’s chairman of the board and chief executive officer, emphasized, “We have worked with Liam over the past 30 years and are excited to bring his extensive lodging expertise to our board. His resume speaks for itself, and his addition to the board brings substantial insights from both an operations and franchisor/franchisee relationship perspective that will be very helpful as we enhance shareholder value through continued focus on maximizing operating results and critical analysis of capital allocation decisions.”

Brown currently serves on the board of EPR Properties (NYSE: EPR), a publicly traded diversified experiential net lease REIT, where he is a member of the Compensation & Human Capital Committee (chair) and the Nominating/Company Governance Committee. He also serves on the Executive Committee of the American Hotel and Lodging Association. He holds a Hotel Diploma and Business Degree from the Dublin Institute of Technology, Trinity College and earned his Master of Business Administration from the Robert H. Smith School of Management at the University of Maryland.

About Chatham Lodging Trust

Chatham Lodging Trust is a self-advised, publicly-traded real estate investment trust focused primarily on investing in upscale, extended-stay hotels and premium-branded, select-service hotels. Additional information about Chatham may be found at chathamlodgingtrust.com.

Included in this press release are certain “non-GAAP financial measures,” within the meaning of Securities and Exchange Commission (SEC) rules and regulations, that are different from measures calculated and presented in accordance with GAAP (generally accepted accounting principles). The company considers the following non-GAAP financial measures useful to investors as key supplemental measures of its operating performance: (1) FFO, (2) Adjusted FFO, (3) EBITDA, and (4) Adjusted EBITDA. These non-GAAP financial measures could be considered along with, but not as alternatives to, net income or loss, cash flows from operations or any other measures of the company’s operating performance prescribed by GAAP.

Contact:  
Dennis Craven (Company) Chris Daly (Media)
Chief Operating Officer DG Public Relations
(561) 227-1386 (703) 864-5553

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.